Vanda Pharmaceuticals (VNDA) said Monday that it submitted a new drug application with the US Food and Drug Administration requesting marketing approval for Bysanti to treat acute bipolar I disorder and schizophrenia.
The company started a phase 3 study of the drug as a once-daily add-on treatment for major depressive order in Q4, with results expected in 2026.
Shares of the company were down 2.1% in recent trading.
Price: 4.59, Change: -0.10, Percent Change: -2.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.